Benitec Biopharma (BNTC)
Market Price (2/15/2026): $10.38 | Market Cap: $477.2 MilSector: Health Care | Industry: Biotechnology
Benitec Biopharma (BNTC)
Market Price (2/15/2026): $10.38Market Cap: $477.2 MilSector: Health CareIndustry: Biotechnology
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -39% | Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more. | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -51 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -14% | |
| Significant short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 19.44 | |
| Key risksBNTC key risks include [1] a critical dependency on the clinical trial success of its lead candidate, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -39% |
| Megatrend and thematic driversMegatrends include Biotechnology & Genomics, and Precision Medicine. Themes include Gene Editing & Therapy, Targeted Therapies, Show more. |
| Very low revenueRev LTMTotal Revenue or Sales, Last Twelve Months is 0 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -51 Mil |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -14% |
| Significant short interestShort Interest Days-to-CoverDTC = (Short Interest Share Quantity) / (Average Daily Trading Volume). Reflects how many days it would take to cover (close out) the short interest based on average volumes. High DTC can signify an increased risk of a short squeeze. is 19.44 |
| Key risksBNTC key risks include [1] a critical dependency on the clinical trial success of its lead candidate, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Benitec Biopharma (BNTC) stock has lost about 35% since 10/31/2025 because of the following key factors:
1. Public Offering and Potential Dilution
Benitec Biopharma undertook a public offering in early November 2025, pricing a $100 million common stock offering at $13.50 per share. While this infusion of capital strengthened the company's financial position, the increase in outstanding shares typically leads to dilution, which can exert downward pressure on the value of existing shares.
2. Increased Operating Expenses and Widening Net Losses
The company reported a significant increase in operating expenses and a widening net loss for its second fiscal quarter ended December 31, 2025. Total expenses for this quarter rose to $13.4 million, compared to $10.8 million in the corresponding period of the previous year. Furthermore, the net loss for the six-month period ending December 31, 2025, expanded to $20.8 million, up from $14.6 million a year earlier, driven by sustained investment in research and development and higher general and administrative costs.
Show more
1. Public Offering and Potential Dilution
Benitec Biopharma undertook a public offering in early November 2025, pricing a $100 million common stock offering at $13.50 per share. While this infusion of capital strengthened the company's financial position, the increase in outstanding shares typically leads to dilution, which can exert downward pressure on the value of existing shares.
2. Increased Operating Expenses and Widening Net Losses
The company reported a significant increase in operating expenses and a widening net loss for its second fiscal quarter ended December 31, 2025. Total expenses for this quarter rose to $13.4 million, compared to $10.8 million in the corresponding period of the previous year. Furthermore, the net loss for the six-month period ending December 31, 2025, expanded to $20.8 million, up from $14.6 million a year earlier, driven by sustained investment in research and development and higher general and administrative costs.
Show more
Stock Movement Drivers
Fundamental Drivers
The -36.6% change in BNTC stock from 10/31/2025 to 2/15/2026 was primarily driven by a -10.5% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 10312025 | 2152026 | Change |
|---|---|---|---|
| Stock Price ($) | 16.36 | 10.38 | -36.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 41 | 46 | -10.5% |
| Cumulative Contribution | 0.0% |
Market Drivers
10/31/2025 to 2/15/2026| Return | Correlation | |
|---|---|---|
| BNTC | -36.6% | |
| Market (SPY) | -0.0% | 34.3% |
| Sector (XLV) | 9.3% | 10.5% |
Fundamental Drivers
The -5.0% change in BNTC stock from 7/31/2025 to 2/15/2026 was primarily driven by a -16.0% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 7312025 | 2152026 | Change |
|---|---|---|---|
| Stock Price ($) | 10.93 | 10.38 | -5.0% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 39 | 46 | -16.0% |
| Cumulative Contribution | 0.0% |
Market Drivers
7/31/2025 to 2/15/2026| Return | Correlation | |
|---|---|---|
| BNTC | -5.0% | |
| Market (SPY) | 8.2% | 24.9% |
| Sector (XLV) | 21.4% | 11.8% |
Fundamental Drivers
The -9.7% change in BNTC stock from 1/31/2025 to 2/15/2026 was primarily driven by a -39.3% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 1312025 | 2152026 | Change |
|---|---|---|---|
| Stock Price ($) | 11.49 | 10.38 | -9.7% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | 0.0% |
| P/S Multiple | ∞ | ∞ | 0.0% |
| Shares Outstanding (Mil) | 28 | 46 | -39.3% |
| Cumulative Contribution | 0.0% |
Market Drivers
1/31/2025 to 2/15/2026| Return | Correlation | |
|---|---|---|
| BNTC | -9.7% | |
| Market (SPY) | 14.3% | 20.5% |
| Sector (XLV) | 8.8% | 13.8% |
Fundamental Drivers
The 165.5% change in BNTC stock from 1/31/2023 to 2/15/2026 was primarily driven by a 9.2233720368547763E17% change in the company's P/S Multiple.| (LTM values as of) | 1312023 | 2152026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.91 | 10.38 | 165.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 0 | |
| P/S Multiple | 34.2 | ∞ | 9.2233720368547763E17% |
| Shares Outstanding (Mil) | 1 | 46 | -98.6% |
| Cumulative Contribution | 0.0% |
Market Drivers
1/31/2023 to 2/15/2026| Return | Correlation | |
|---|---|---|
| BNTC | 165.5% | |
| Market (SPY) | 74.0% | 5.2% |
| Sector (XLV) | 23.7% | 2.4% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| BNTC Return | -13% | -94% | 12% | 291% | 7% | -16% | -78% |
| Peers Return | -21% | 8% | -11% | -15% | 90% | -17% | 1% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -0% | 82% |
Monthly Win Rates [3] | |||||||
| BNTC Win Rate | 42% | 25% | 50% | 58% | 67% | 0% | |
| Peers Win Rate | 45% | 55% | 43% | 38% | 62% | 20% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| BNTC Max Drawdown | -14% | -95% | -33% | -13% | -23% | -16% | |
| Peers Max Drawdown | -36% | -32% | -37% | -33% | -40% | -19% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -1% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ALNY, ARWR, SRPT, IONS, RGNX.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 2/13/2026 (YTD)
How Low Can It Go
| Event | BNTC | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -98.8% | -25.4% |
| % Gain to Breakeven | 8056.5% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -81.6% | -33.9% |
| % Gain to Breakeven | 442.9% | 51.3% |
| Time to Breakeven | Not Fully Recovered days | 148 days |
| 2018 Correction | ||
| % Loss | -89.7% | -19.8% |
| % Gain to Breakeven | 869.3% | 24.7% |
| Time to Breakeven | Not Fully Recovered days | 120 days |
Compare to ALNY, ARWR, SRPT, IONS, RGNX
In The Past
Benitec Biopharma's stock fell -98.8% during the 2022 Inflation Shock from a high on 3/23/2021. A -98.8% loss requires a 8056.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Benitec Biopharma (BNTC)
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
AI Analysis | Feedback
Here are 1-2 brief analogies to describe Benitec Biopharma:
- A developing Alnylam Pharmaceuticals, focused on pioneering RNA interference (RNAi) therapies for genetic diseases.
- Sarepta Therapeutics for rare genetic diseases, but with a gene-silencing (RNAi) technology approach.
AI Analysis | Feedback
- BB-301: An investigational gene therapy being developed for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a rare genetic muscle-wasting disorder.
AI Analysis | Feedback
Benitec Biopharma (BNTC)
Benitec Biopharma (BNTC) is a clinical-stage biotechnology company focused on developing novel genetic medicines. As a clinical-stage company, it does not currently have approved commercial products for sale. Therefore, it does not sell products directly to individuals or generate revenue from product sales to end-users.
Benitec Biopharma's revenue generation primarily stems from research grants, licensing agreements, and collaborations with other companies in the pharmaceutical and biotechnology sectors, rather than direct sales of commercial products to customers.
The company sells primarily to other companies through licensing and collaboration agreements. Based on their SEC filings (e.g., Form 10-K), a key partner and source of non-recurring revenue from a license agreement is:
- AXONIS Therapeutics, Inc. (This is a privately held company, so no public symbol is available.)
Benitec Biopharma also receives grant revenue, typically from governmental bodies or non-profit organizations supporting research and development, which are not considered commercial customers in the traditional sense.
AI Analysis | Feedback
Jerel Banks, M.D., Ph.D. Chief Executive Officer & Chairman of the Board
Dr. Jerel Banks has served as a Director of Benitec Biopharma since October 2016, Chairman of the Board since October 2017, and Chief Executive Officer since June 2018. Previously, he was the Chief Investment Officer of Nant Capital, LLC. From 2012 to 2015, Dr. Banks was Vice President, Portfolio Manager, and Research Analyst for the Franklin Biotechnology Discovery Fund at Franklin Templeton Investments. He also worked as a biotechnology equity research analyst at Sectoral Asset Management from 2011 to 2012 and at Apothecary Capital, the healthcare investment management team for the Bass Family, from 2008 to 2011. He began his career in investment management as a healthcare equity research associate at Capital Research Company (2006-2008). Dr. Banks earned an M.D. from the Brown University School of Medicine and a Ph.D. in Organic Chemistry from Brown University, and holds an A.B. in Chemistry from Princeton University.
Megan Boston Chief Financial Officer & Director
Megan Boston was appointed Chief Financial Officer effective January 1, 2025, in addition to her role as Company Secretary. She has been a Director of Benitec since August 2016 and an Executive Director since June 2018. From 2014 until joining Benitec, Ms. Boston served as Chief Executive Officer and Managing Director of several companies listed on the Australian Stock Exchange, including Omni Market Tide Ltd and Rision Ltd. She previously held senior executive roles in risk and compliance at various banking institutions and worked for PricewaterhouseCoopers. Ms. Boston holds a Bachelor of Commerce, is an Australian Chartered Accountant, and has completed the company directors course diploma administered by the Australian Institute of Company Directors.
Sophie Mukadam Chief Operating Officer
Sophie Mukadam was appointed Chief Operating Officer effective January 1, 2025. She has been with Benitec since May 2019, serving as Associate Director, Program Management since 2021 and previously as Senior Program Manager from 2019 to 2021. Between 2018 and 2019, Ms. Mukadam worked as a regulatory affairs professional at Premier Consulting. Her prior experience from 2003 to 2018 includes scientific research positions at Genentech, Bristol-Myers Squibb, and Pfizer. Ms. Mukadam holds a B.A. in Molecular and Cell Biology from the University of California, Berkeley, and a Certificate in Project Management for Biotechnology.
AI Analysis | Feedback
Key Risks to Benitec Biopharma (BNTC)
- Clinical Trial Outcomes and Regulatory Approval: As a development-stage biotechnology company, Benitec Biopharma's future and financial viability are critically dependent on the successful outcomes of its clinical trials, particularly for its lead candidate BB-301 for Oculopharyngeal Muscular Dystrophy (OPMD), and subsequent regulatory approvals. The company currently generates no revenue from product sales. Any clinical failure, such as safety concerns or lack of efficacy in ongoing or future trials, or an inability to secure necessary regulatory approvals (e.g., from the FDA), would be catastrophic for the business.
- Funding and Cash Burn Rate: Benitec Biopharma operates without product revenue and incurs significant research and development as well as general and administrative expenses, leading to substantial net losses. The company relies on equity financing, debt, grants, or collaborations to fund its operations. While Benitec has cash reserves and a projected cash runway, its increasing burn rate necessitates continuous monitoring. There is an ongoing risk of needing additional capital, which could lead to further dilution for existing shareholders through new stock offerings.
- Intellectual Property and Competition: The company's business model is built upon its proprietary "Silence and Replace" DNA-directed RNA interference (ddRNAi) platform. Protecting and enforcing its patents and other intellectual property rights is crucial. Furthermore, Benitec Biopharma faces competition from other companies developing gene therapy approaches, which could impact its market share and commercial success if its product candidates reach the market.
AI Analysis | Feedback
nullAI Analysis | Feedback
Benitec Biopharma's main product, BB-301, targets Oculopharyngeal Muscular Dystrophy (OPMD). The addressable markets for OPMD are as follows:- The global OPMD market was valued at over USD 4.56 billion in 2024 and is projected to reach USD 25.33 billion by 2037, growing at a compound annual growth rate (CAGR) of approximately 14.1% between 2025 and 2037. The market size for OPMD in 2025 is estimated at USD 5.11 billion.
- The U.S. OPMD market was valued at approximately USD 0.51 billion in 2022 and is projected to reach USD 0.78 billion by 2030, demonstrating a CAGR of 5.6% during the forecast period of 2023-2030.
- North America is expected to hold the largest revenue share, 36%, of the OPMD market by 2037.
- The Asia Pacific OPMD market is estimated to be the second largest, with about a 29% revenue share by the end of 2037.
- The OPMD market in Spain was valued at around USD 23.16 million in 2022 and is projected to reach USD 38.62 million by 2030, with a CAGR of 6.6% from 2023 to 2030.
AI Analysis | Feedback
Here are 3-5 expected drivers of future revenue growth for Benitec Biopharma (BNTC) over the next 2-3 years:- Successful Clinical Development and Regulatory Approval of BB-301 for OPMD: Benitec Biopharma's primary revenue growth driver is the successful progression and eventual regulatory approval of its lead gene therapy candidate, BB-301, for Oculopharyngeal Muscular Dystrophy (OPMD). The company has reported positive interim clinical study results for the BB-301 Phase 1b/2a Clinical Trial and has received FDA Fast Track Designation and Orphan Drug Designation from both the FDA and EMA for BB-301. Continued positive clinical outcomes and subsequent market authorization would be critical for generating revenue from product sales.
- Expansion of BB-301 Development to Additional OPMD Cohorts/Doses: The ongoing Phase 1b/2a clinical study of BB-301 is designed to enroll additional subjects into Cohort 2 at a higher dose, following positive recommendations from the Independent Data Safety Monitoring Board. Further successful advancement through these cohorts, demonstrating safety and efficacy at potentially optimal dosing, would strengthen the drug's profile and market potential, paving the way for broader patient access and revenue generation.
- Development of New Product Candidates utilizing the "Silence and Replace" ddRNAi Platform: Benitec Biopharma's proprietary "Silence and Replace" DNA-directed RNA interference (ddRNAi) platform is a foundational asset designed to create genetic medicines for chronic and life-threatening human conditions. Beyond BB-301, the successful advancement of other pipeline programs, such as BB-103 for chronic hepatitis B virus infection, would diversify future revenue streams through new product launches.
- Strategic Partnerships and Licensing Agreements: As a clinical-stage biotechnology company, Benitec Biopharma's future revenue could also be driven by strategic collaborations, partnerships, or licensing agreements related to its ddRNAi platform or specific product candidates. While recent financing activities have focused on public offerings, future agreements with larger pharmaceutical companies could provide non-dilutive funding through upfront payments, milestone achievements, and potential royalties on future product sales.
AI Analysis | Feedback
Share Issuance
- In November 2025, Benitec Biopharma priced an underwritten public offering of 5,930,000 shares and a concurrent registered direct offering of 1,481,481 shares to Suvretta Capital, both at $13.50 per share, with expected aggregate gross proceeds of approximately $100 million. The company granted underwriters a 30-day option to purchase up to an additional 889,500 shares. The net proceeds are intended for product candidate development, working capital, and general corporate purposes.
- In March 2025, Benitec Biopharma completed a common stock offering, raising approximately $30 million in gross proceeds through a combined stock offering priced at $13.00 per share, which included a strategic investment from Suvretta Capital. The net proceeds from this financing were intended to support product candidate development, working capital, and general corporate purposes.
- In April 2024, the company secured $40 million in funding through a private placement at $4.80 per share, which was led by Suvretta Capital. This financing was noted as sufficient to fund operations through 2025.
Inbound Investments
- Suvretta Capital participated as a long-term investor in Benitec Biopharma's $100 million common stock offerings in November 2025.
- Suvretta Capital made a strategic investment as part of Benitec's $30 million common stock offering in March 2025.
- In November 2024, Suvretta Capital Management acquired 5,500,884 shares of Benitec Biopharma Inc. at $10.4 per share, increasing its total holdings to 14,329,937 shares.
Outbound Investments
- Benitec Biopharma Limited has acquired Tacere Therapeutics.
Capital Expenditures
- Information regarding specific dollar values of capital expenditures or expected capital expenditures for the upcoming year for Benitec Biopharma is not explicitly available in the provided search results within the last 3-5 years. However, the company reported research and development expenses of $18.3 million in 2025, up from $15.6 million in 2024, primarily related to the ongoing clinical development of its lead therapeutic candidate, BB-301, for Oculopharyngeal Muscular Dystrophy (OPMD).
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 40.73 |
| Mkt Cap | 5.3 |
| Rev LTM | 1,029 |
| Op Inc LTM | -68 |
| FCF LTM | -62 |
| FCF 3Y Avg | -196 |
| CFO LTM | -61 |
| CFO 3Y Avg | -142 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 65.2% |
| Rev Chg 3Y Avg | 40.6% |
| Rev Chg Q | 22.9% |
| QoQ Delta Rev Chg LTM | 3.6% |
| Op Mgn LTM | -3.6% |
| Op Mgn 3Y Avg | -55.1% |
| QoQ Delta Op Mgn LTM | 5.3% |
| CFO/Rev LTM | -10.1% |
| CFO/Rev 3Y Avg | -52.4% |
| FCF/Rev LTM | -16.1% |
| FCF/Rev 3Y Avg | -57.4% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 5.3 |
| P/S | 8.0 |
| P/EBIT | -5.4 |
| P/E | -4.4 |
| P/CFO | -5.6 |
| Total Yield | -5.8% |
| Dividend Yield | 0.0% |
| FCF Yield 3Y Avg | -10.4% |
| D/E | 0.1 |
| Net D/E | -0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -11.8% |
| 3M Rtn | -13.5% |
| 6M Rtn | -14.5% |
| 12M Rtn | 15.6% |
| 3Y Rtn | 68.2% |
| 1M Excs Rtn | -13.0% |
| 3M Excs Rtn | -12.0% |
| 6M Excs Rtn | -18.3% |
| 12M Excs Rtn | 1.2% |
| 3Y Excs Rtn | 4.1% |
Price Behavior
Price Behavior
| Market Price | $10.38 | |
| Market Cap ($ Bil) | 0.4 | |
| First Trading Date | 08/18/2015 | |
| Distance from 52W High | -38.2% | |
| 50 Days | 200 Days | |
| DMA Price | $12.31 | $13.35 |
| DMA Trend | down | down |
| Distance from DMA | -15.7% | -22.3% |
| 3M | 1YR | |
| Volatility | 63.0% | 66.0% |
| Downside Capture | 201.80 | 105.58 |
| Upside Capture | 50.49 | 84.09 |
| Correlation (SPY) | 32.3% | 20.9% |
BNTC Betas & Captures as of 1/31/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.36 | 2.79 | 2.20 | 1.24 | 0.68 | 0.33 |
| Up Beta | 4.46 | 2.85 | -0.07 | 1.00 | 0.83 | 0.73 |
| Down Beta | 0.09 | 3.71 | 3.27 | 1.26 | 0.43 | 0.48 |
| Up Capture | -144% | 206% | 138% | 138% | 64% | 9% |
| Bmk +ve Days | 11 | 22 | 34 | 71 | 142 | 430 |
| Stock +ve Days | 9 | 24 | 34 | 72 | 134 | 375 |
| Down Capture | 60% | 231% | 282% | 136% | 81% | -30% |
| Bmk -ve Days | 9 | 19 | 27 | 54 | 109 | 321 |
| Stock -ve Days | 11 | 17 | 26 | 50 | 111 | 360 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with BNTC | |
|---|---|---|---|---|
| BNTC | -3.9% | 67.5% | 0.22 | - |
| Sector ETF (XLV) | 9.6% | 17.4% | 0.37 | 14.2% |
| Equity (SPY) | 14.0% | 19.4% | 0.55 | 20.6% |
| Gold (GLD) | 74.3% | 25.3% | 2.17 | 5.1% |
| Commodities (DBC) | 7.0% | 16.7% | 0.24 | 7.3% |
| Real Estate (VNQ) | 7.9% | 16.6% | 0.28 | 15.6% |
| Bitcoin (BTCUSD) | -29.8% | 44.9% | -0.65 | 17.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with BNTC | |
|---|---|---|---|---|
| BNTC | -34.8% | 136.1% | 0.16 | - |
| Sector ETF (XLV) | 8.0% | 14.5% | 0.37 | 4.6% |
| Equity (SPY) | 13.3% | 17.0% | 0.62 | 9.3% |
| Gold (GLD) | 22.1% | 17.0% | 1.06 | 3.2% |
| Commodities (DBC) | 10.5% | 18.9% | 0.44 | 1.0% |
| Real Estate (VNQ) | 5.2% | 18.8% | 0.18 | 8.8% |
| Bitcoin (BTCUSD) | 8.3% | 57.2% | 0.37 | 6.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with BNTC | |
|---|---|---|---|---|
| BNTC | -34.2% | 133.9% | 0.19 | - |
| Sector ETF (XLV) | 11.2% | 16.5% | 0.56 | 4.7% |
| Equity (SPY) | 15.6% | 17.9% | 0.75 | 6.3% |
| Gold (GLD) | 15.3% | 15.6% | 0.82 | 3.2% |
| Commodities (DBC) | 8.1% | 17.6% | 0.38 | 1.3% |
| Real Estate (VNQ) | 6.4% | 20.7% | 0.27 | 5.3% |
| Bitcoin (BTCUSD) | 67.9% | 66.7% | 1.07 | 5.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 2/12/2026 | -2.7% | ||
| 9/22/2025 | -2.1% | 3.6% | 17.4% |
| 5/14/2025 | 3.0% | 5.7% | 20.8% |
| 2/14/2025 | 16.0% | 16.5% | 58.1% |
| 9/26/2024 | 5.0% | 11.6% | 25.0% |
| 5/13/2024 | -12.2% | 2.6% | -18.9% |
| 2/13/2024 | 0.0% | 3.9% | 82.1% |
| 9/21/2023 | 0.3% | 1.4% | 16.0% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 7 | 8 | 7 |
| # Negative | 8 | 6 | 7 |
| Median Positive | 1.3% | 3.7% | 20.8% |
| Median Negative | -4.2% | -5.6% | -28.2% |
| Max Positive | 16.0% | 16.5% | 82.1% |
| Max Negative | -12.2% | -21.7% | -55.6% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 12/31/2025 | 02/12/2026 | 10-Q |
| 09/30/2025 | 11/14/2025 | 10-Q |
| 06/30/2025 | 09/22/2025 | 10-K |
| 03/31/2025 | 05/14/2025 | 10-Q |
| 12/31/2024 | 02/14/2025 | 10-Q |
| 09/30/2024 | 11/14/2024 | 10-Q |
| 06/30/2024 | 09/26/2024 | 10-K |
| 03/31/2024 | 05/13/2024 | 10-Q |
| 12/31/2023 | 02/13/2024 | 10-Q |
| 09/30/2023 | 11/13/2023 | 10-Q |
| 06/30/2023 | 09/21/2023 | 10-K |
| 03/31/2023 | 05/15/2023 | 10-Q |
| 12/31/2022 | 02/13/2023 | 10-Q |
| 09/30/2022 | 11/10/2022 | 10-Q |
| 06/30/2022 | 09/02/2022 | 10-K |
| 03/31/2022 | 05/16/2022 | 10-Q |
Insider Activity
Expand for More| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Suvretta, Capital Management, Llc | See footnotes | Buy | 12292025 | 12.85 | 50,000 | 642,500 | 123,617,964 | Form | |
| 2 | Suvretta, Capital Management, Llc | See footnotes | Buy | 12292025 | 13.10 | 16,836 | 220,552 | 126,210,574 | Form | |
| 3 | Suvretta, Capital Management, Llc | See footnotes | Buy | 12292025 | 13.44 | 77,387 | 1,040,081 | 130,370,621 | Form | |
| 4 | Suvretta, Capital Management, Llc | See footnotes | Buy | 12222025 | 11.24 | 10,215 | 114,817 | 107,306,875 | Form | |
| 5 | Suvretta, Capital Management, Llc | See footnotes | Buy | 12222025 | 11.48 | 16,384 | 188,088 | 109,758,271 | Form |
Industry Resources
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.